Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTX-001 in Adult Healthy Participants and Participants With Nonobstructive Hypertrophic Cardiomyopathy
NCT07867288Phase 1Recruiting
- Sponsor
- HAYA Therapeutics
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of HTX-001 in hypertrophic cardiomyopathy (HCM), sponsored by HAYA Therapeutics. Primary endpoint: Safety and Tolerability at Day 43. Started Oct 2026; status: recruiting.
02
Drugs
HTX-001
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07867288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867288.